

REMARKS

1. Before examination of this application, please amend the application as shown above.
2. None of the amendments introduce new matter, as shown by the citations in the following table:

<u>Claim</u>	<u>Supported by</u>
21	Page 31, Formula VI
22	Figure 1K; Figure 2K; page 85, Example 10
23	Page 49, Formula XII and Page 46, Formula X
24	Page 47, lines 16-27.
25	Page 49, Structure 13; Fig. 1M; page 88, Example 11
26	Page 53, Formula XIII
27	Page 53, lines 14-15
28	Page 53, lines 15-16
29	Page 54, Structure 17; Fig. 1Q; Figure 2-O; page 100, Example 15
30	Page 12, lines 1-12; pages 101-103, Examples 16-18
31	Page 12, lines 12-17
32	Page 12, lines 7-9
33	Page 14, lines 16-29; Page 40, line 3-page 41, line 4
34	Page 14, lines 16-19
35	Page 46, lines 11-15; Page 15, lines 1-21;

- Page 14, lines 22-25
- 36 Page 40, line 3-page 41, line 4; Page 15,
lines 1-12
- 37 Page 14, lines 20-22; page 15, lines 12-
16; page 46, lines 6-15
- 38 Page 42, lines 16-22
- 39 Page 15, line 22-page 16, line 8; page
57, line 1-page 62, line 5; page 101, line
17-page 103, line 25
- 40 Page 15, line 22- page 16, line 8; page 57,
line 1-page 62, line 5; page 105, line 12-
page 110, line 4
- 41 Page 15, line 22-page 16, line 8; page 57,
line 1-page 62, line 5; page 103, Example
18; Figure 13
- 42 Page 15, line 22- page 16, line 8; page 57,
line 1-page 62, line 5

Correction in
specification

Formula III

Supported by

Much of the structure is shown in the
specification. See also Claim 9; also
see Formula III on page 19 in
Provisional Application Ser. No.
60/146,648, filed 7/30/99, which is the
priority application for the instant
application.

Formula X

Much of the structure is shown in the specification; see also page 47, line 4-page 49, line 3, including Formulas XI and XII. See also Provisional Application Ser. No. 60/146,648, filed 7/30/99, which is the priority application for the instant application, on page 33.

Example 10

In the title of Example 10 on page 85, lines 2-3, the numbers used to identify 2-OH-Spiroacridine and 2-Phos-Spiroacridan were 12 and 11, respectively. In the discussion of these 2 compounds on page 86, line 28 and page 87, line 16, the numbers 11 and 12 were reversed. This amendment corrects the numbers on pages 86 and 87 so that they are now consistent with the title.

3. Please note that, under separate cover, the correspondence address for this application has been changed to the following:

Patrick Igoe
Patent Counsel
Bayer Corporation
511 Benedict Avenue
Tarrytown, NY 10591-5097

-14-

Tel. 914-524-2684

Fax 914-524-3594

The Examiner is encouraged to telephone the undersigned attorney to discuss any matter which would expedite allowance of the present application.

Respectfully submitted,

QINGPING JIANG ET AL.

By: Arthur S. Morgenstern
Arthur S. Morgenstern
Registration No. 28,244
Attorney for Applicants

WEINGARTEN, SCHURGIN,
GAGNEBIN & HAYES LLP

Ten Post Office Square
Boston, MA 02109
Telephone: (617) 542-2290
Telecopier: (617) 451-0313

Dated: 11/8/00

ASM/jds
232020v3